TREATMENT FOR OSTEOPOROSIS OF THE HIP

Project: Research project

Description

Bone loss from the proximal femur continues into the nineties and low bone
mass leads to an increased susceptibility to fracture. The risk of
fracture accelerates between age 80-90 so that 33% of women and 17% of men
sustain a hip fracture. Hip fractures cause an immediate 15% mortality,
and will cost 20 billion dollars annually within 20 years. Two major factors play a role in the bone loss. Estrogen deficiency after
the menopause is associated with increased bone loss from the femur. In
the mid sixties a second factor emerges - malabsorption of calcium, which
increases the degree of negative calcium balance causing secondary
hyperparathyroidism and bone loss. By correcting estrogen deficiency and
malabsorption of calcium it may be possible to reverse bone loss from the
proximal femur. In order to test this hypothesis, 500 osteopenic women
aged between 65-77 years will be treated with either estrogen, 1 alpha-
hydroxyvitamin D2 (1 alpha-OH-D2) or a combination of estrogen and 1 alpha-
OH-D2 for 3 years in an attempt to reverse bone loss from the proximal
femur. It is suggested that estrogen will inhibit bone resorption and 1
alpha-OH-D2 will stimulate bone formation, and that the combination will be
more effective than single therapy. The study will be double blind and
placebo controlled. The primary outcome will be bone mineral density of the proximal femur,
however, other areas of the skeleton will be measured so that any effect of
therapy which might cause redistribution of bone mineral from cortex to
trabecular sites can be detected. Loss of cortical bone could increase
fracture susceptibility. Reversing bone loss from the proximal femur from age 65 for several years
could maintain bone density above the fracture threshold and significantly
reduce the risk of fracture. Not only would this provide considerable
individual health benefits, but also greatly reduce health care costs.
StatusFinished
Effective start/end date9/30/918/31/01

Funding

  • National Institutes of Health: $538,974.00
  • National Institutes of Health: $739,664.00
  • National Institutes of Health
  • National Institutes of Health: $68,258.00
  • National Institutes of Health
  • National Institutes of Health: $70,988.00
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health: $66,751.00
  • National Institutes of Health
  • National Institutes of Health: $121,169.00
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health

Fingerprint

Osteoporosis
Hip
Bone and Bones
Femur
Estrogens
Hip Fractures
Therapeutics
Calcium
Bone Density
Insurance Benefits
Bone Resorption
Menopause
Osteogenesis
Skeleton
Health Care Costs
Minerals
Costs and Cost Analysis
Mortality
hydroxide ion